Samsung Bioepis Urges Oncology Systems To Share Biosimilar Success Stories
Lack Of Physician Confidence Remains Barrier To Biosimilar Adoption
Prescribers must better understand how biosimilars work and why they are safe to use, in order to ensure continued biosimilar uptake, Samsung Bioepis believes.
You may also be interested in...
Samsung Bioepis has expanded its portfolio of biosimilar products in its domestic South Korea, with the launch of bevacizumab via partner Boryung Pharmaceutical.
Acknowledging that “different companies have different views and approaches about interchangeability,” Samsung Bioepis has once again called into question the controversial designation.
Amgen’s biosimilars sales will almost certainly smash through the $2bn barrier in 2021, driven by the strength of its product portfolio including bevacizumab and trastuzumab. The California-based biotech has warned, however, that greater competition will naturally lead to pricing challenges.